Individual long-term variation of platelet reactivity in patients with dual antiplatelet therapy after myocardial infarction

References

• The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827–830. doi:10.1016/0140-6736(90)92336-G.
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000;21:2033–2041. doi:10.1053/euhj.2000.2474.
   PubMed Web of Science ®Google Scholar
• Mehta SR. Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI-CURE. J Invasive Cardiol. 2003;15 Suppl B:17B–20B. discussion 20B-21B.
   PubMedGoogle Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45:246–251. doi:10.1016/j.jacc.2004.09.067.
   PubMed Web of Science ®Google Scholar
• Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med. 2002;252:233–238. doi:10.1046/j.1365-2796.2002.01027.x.
   PubMed Web of Science ®Google Scholar
• Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171–3175. doi:10.1161/01.CIR.0000130846.46168.03.
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, Bonnet JL, Alessi MC. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006;4:542–549. doi:10.1111/j.1538-7836.2005.01751.x.
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006;48:1742–1750. doi:10.1016/j.jacc.2006.06.065.
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097–1105. doi:10.1001/jama.2011.290.
   PubMed Web of Science ®Google Scholar
• Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U, Richardt G, Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59:2159–2164.
   PubMed Web of Science ®Google Scholar
• Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrie D, Boueri Z, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367:2100–2109. doi:10.1056/NEJMoa1209979.
   PubMed Web of Science ®Google Scholar
• Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, Bellemain-Appaix A, Range G, El Mahmoud R, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016;388:2015–2022. doi:10.1016/S0140-6736(16)31323-X.
   PubMed Web of Science ®Google Scholar
• Saw J, Madsen EH, Chan S, Maurer-Spurej E. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol. 2008;52:1826–1833. doi:10.1016/j.jacc.2008.08.047.
   PubMed Web of Science ®Google Scholar
• Jaitner J, Stegherr J, Morath T, Braun S, Bernlochner I, Schomig A, Kastrati A, Sibbing D. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost. 2011;105:107–112. doi:10.1160/TH10-07-0440.
   PubMed Web of Science ®Google Scholar
• Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011;57:2474–2483. doi:10.1016/j.jacc.2010.12.047.
   PubMed Web of Science ®Google Scholar
• Codner P, Vaduganathan M, Rechavia E, Iakobishvili Z, Greenberg G, Assali A, Hasdai D, Battler A, Kornowski R, Lev EI. Clopidogrel response up to six months after acute myocardial infarction. Am J Cardiol. 2012;110:321–325. doi:10.1016/j.amjcard.2012.03.029.
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Ruff CT, Mesa RA, Mattimore JF, Cyr JF, Lei L, Frelinger AL 3rd, Michelson AD, Berg DD, Angiolillo DJ, et al. Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol. 2014;64:361–368. doi:10.1016/j.jacc.2014.03.051.
   PubMed Web of Science ®Google Scholar
• Tello-Montoliu A, Rivera J, Hernandez D, Silvente A, Jover E, Rodriguez AI, Quintana M, Romero A, Orenes-Pinero E, Rivera-Caravaca JM, et al. Temporal changes in platelet response in acute coronary syndrome patients with prasugrel and clopidogrel after stent implantation. Circ J. 2018;82:353–360. doi:10.1253/circj.CJ-17-0471.
   PubMed Web of Science ®Google Scholar
• Nuhrenberg TG, Stratz C, Leggewie S, Hochholzer W, Valina CM, Gick M, Kirtane AJ, Stone GW, Neumann FJ, Trenk D. Temporal variability in the antiplatelet effects of clopidogrel and aspirin after elective drug-eluting stent implantation. An ADAPT-DES substudy. Thromb Haemost. 2015;114:1020–1027. doi:10.1160/TH15-03-0257.
   PubMed Web of Science ®Google Scholar
• Alfredsson J, Lindahl TL, Gustafsson KM, Janzon M, Jonasson L, Logander E, Nilsson L, Swahn E. Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel: results from Assessing Platelet Activity in Coronary Heart Disease (APACHE). Thromb Res. 2015;136:335–340. doi:10.1016/j.thromres.2015.05.021.
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, et al. Universal definition of myocardial infarction. Circulation. 2007;116:2634–2653. doi:10.1161/CIRCULATIONAHA.107.187397.
   PubMed Web of Science ®Google Scholar
• Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost. 2006;96:781–788. doi:10.1160/TH06-05-0242.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Steinhubl SR, Schulz S, Schomig A, Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol. 2010;56:317–318. doi:10.1016/j.jacc.2010.03.048.
   PubMed Web of Science ®Google Scholar
• Mayer K, Bernlochner I, Braun S, Schulz S, Orban M, Morath T, Cala L, Hoppmann P, Schunkert H, Laugwitz KL, et al. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. J Am Coll Cardiol. 2014;64:863–871. doi:10.1016/j.jacc.2014.05.049.
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Trenk D, Schror K, Gawaz M, Kristensen SD, Storey RF, Huber K, European Platelet A. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors–is an algorithm the answer? Thromb Haemost. 2015;113:37–52. doi:10.1160/TH14-03-0238.
   PubMed Web of Science ®Google Scholar
• Freynhofer MK, Bruno V, Brozovic I, Jarai R, Vogel B, Farhan S, Hubl W, Willheim M, Wojta J, Huber K. Variability of on-treatment platelet reactivity in patients on clopidogrel. Platelets. 2014;25:328–336. doi:10.3109/09537104.2013.827781.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schomig A, Kastrati A, von Beckerath N. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101:714–719.
   PubMed Web of Science ®Google Scholar
• Kozinski M, Bielis L, Wisniewska-Szmyt J, Boinska J, Stolarek W, Marciniak A, Kubica A, Grabczewska Z, Navarese EP, Andreotti F, et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets. 2011;22:579–587. doi:10.3109/09537104.2011.582900.
   PubMed Web of Science ®Google Scholar
• Refaai MA, Frenkel E, Sarode R. Platelet aggregation responses vary over a period of time in healthy controls. Platelets. 2010;21:460–463. doi:10.3109/09537104.2010.485256.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–260. doi:10.1093/eurheartj/ehx419.
   Google Scholar